RESUMEN

La neumonía adquirida en la comunidad (NAC) sigue siendo una importante causa de morbimortalidad en todo el mundo a pesar de los avances en la ciencia médica. La incidencia de NAC varía de 2 a 5 casos por 100,000 habitantes, y es la principal causa de muerte debido a una infección a través del mundo. Aproximadamente, cuatro millones de casos ocurren anualmente en los Estados Unidos, siendo Streptococcus pneumoniae el patógeno más frecuentemente encontrado.

PALABRAS CLAVE

.

REFERENCIAS

1. Mandell LA. Antimicrobial resistance and treatment of community-acquired pneumonia. Clin Chest Med 2005;26:57-64.

2. Nathawani D, Rubinstein E, Barlow G, Davey P. Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? Clin Infect Dis 2001;32:728-741.

3. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-1754.

4. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72.

5. Lim WS, Baudouin SV, George RC, et al. BTS guidelines of the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64;iii1-iii55.

6. Höffken G, Lorenz J, Kern W, et al. Guidelines of the Paul-Ehrlich-Society of Chemotherapy, the German Respiratory Diseases Society, the German Infectious Diseases Society and the Compentence Network CAPNETZ for the Management of Lower Respiratory Tract Infections and Community-acquired Pneumonia. Pneumonologie 2010;64:149-154.

7. Valencia M, Badia JR, Cavalcanti M, et al. Pneumonia severity index class V patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest 2007;132:515-522.

8. Phua J, See KC, Chan YH, et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax 2009;64:598-603.

9. McNally M, Curtain J, O’Brien KK, Dimitrov BD, Fahey T. Validity of British Thoracic Society guidance (the CRB-65 rule) for predicting the severity of pneumonia in general practice: systematic review and meta-analysis. Br J Gen Pract 2010;60:e423-433 doi: 10.3399/bjgp10X532422.

10. Loke YK, Kwok CS, Niruban A, Myint PK. Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. Thorax 2010;65:884-890.

11. McCormick D, Fine MJ, Coley C, et al. Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes? Am J Med 1999;107:5-12.

12. Garau J, Baquero F, Pérez-Trallero E, et al. NACER Group. Factors impacting on lenght of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect 2008;14:322-329.

13. Huang JQ, Hooper PM, Marrie TJ. Factors associated with length of stay in hospital for suspected community-acquired pneumonia. Can Respir J 2006;13:317-324.

14. Menéndez R, Torres A, Reyes S. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J 2012;39:156-162.

15. Báez SR, Gómez ZC, López EC, et al. Neumonía adquirida en la comunidad. Revisión y actualización con una perspectiva orientada a la calidad de la atención médica. Neumol Cir Torax 2013;72 Supl 1:6-43.